Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure (ULTIMATE-HF)

Trial Profile

Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure (ULTIMATE-HF)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Udenafil (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms ULTIMATE-HF
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2014 Primary endpoint 'Maximal-oxygen-consumption' has been met according to results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top